Showing 91-100 of 454 results
Helsinn, the Swiss Group focused on building quality cancer care products and Purdue Pharma Canada today announce that they have signed an exclusive agreement for the distribution and licensing of Akynzeo®, the oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).
•Collaboration plans a comprehensive range of clinical studies to evaluate Helsinn commercialized and/or under development pipeline products in cancer supportive care and palliative settings • MD Anderson to provide clinical expertise and oncology network.
Helsinn announces annual funding to help talented young physicians achieve their potential
- In the trial, elsiglutide reduced the incidence of chemotherapy-induced diarrhea in colorectal cancer patients receiving 5-FU based chemotherapy regimens, but not sufficiently to meet the primary endpoint for statistical significance - Elsiglutide was observed to be safe and well tolerated in this patient population - Helsinn is working on potential development option...
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is pleased to announce that William Mann, President and Chief Executive Officer of Helsinn’s U.S. subsidiary, Helsinn Therapeutics (U.S.) Inc., will present at the UBS Healthcare Conference at the Grand Hyatt in New York City
Pooled, post-hoc efficacy data analysis from the ROMANA 1 and ROMANA 2 Phase III studies demonstrates that in NSCLC patients with cachexia and a low BMI, anamorelin significantly improves fatigue in addition to symptom burden (including appetite) and increases lean body mass and fat
Helsinn announces that the Company has signed an agreement, with Vifor Pharma (“Vifor”) for the promotion and distribution of Aloxi®, in Spain.
Swiss approval of ALOXI® for paediatric use follows EMA approval in February 2015 and FDA approval in May 2014
A panel of world-renowned experts will share practical recommendations on best practice in supporting people with cancer, offering advice on multidisciplinary approaches and finding practical solutions
Helsinn Group creates new investment fund in 40th anniversary year The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need